This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Neuromuscular diseases  • Neuro-ophthalmology  • Drug Therapy  • Drug Therapy, Other  • Immunologic Disorders  • Alert me on articles by topic

John C. Novak, MD; Amy E. Lovett-Racke, PhD; Michael K. Racke, MD

Arch Neurol. 2008;65(9):1162-1165.

The role of monoclonal antibody (mAb) therapies in treating medical conditions has expanded tremendously since its inception in the 1970s, and their use in neurologic conditions has increased in just the past few years. Currently, mAb treatments are being tested in conditions ranging from neuromuscular disorders to demyelinating diseases. What is now considered experimental therapy may soon become common. In addition, neurologic adverse effects have been reported during the use of mAb therapy in nonneurologic conditions that neurologists should be able to recognize. Because of the rapid increase in the use of mAb treatments, this review highlights their use in neurologic conditions and their neurologic adverse effects.

Author Affiliations: Departments of Neurology (Drs Novak, Lovett-Racke, and Racke) and Molecular Virology, Immunology, and Medical Genetics (Drs Lovett-Racke and Racke), The Ohio State University Medical Center, Columbus.

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(9):1152-1153.
FULL TEXT